An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS)

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

June 19, 2024

Study Completion Date

June 19, 2024

Conditions
Stroke, Acute
Interventions
DEVICE

OTR4132MD

"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."

Trial Locations (3)

33000

CHU Bordeaux Pellegrin, Bordeaux

38000

CHU Grenoble Alpes, Grenoble

54000

CHU Nancy, Nancy

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

European Commission

OTHER

collaborator

Euraxi Pharma

INDUSTRY

lead

Organ, Tissue, Regeneration, Repair and Replacement

INDUSTRY

NCT04083001 - An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS) | Biotech Hunter | Biotech Hunter